Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
11 août 2023 16h05 HE
|
Rani Therapeutics, LLC
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three...
Rani Therapeutics to Participate in August Investor Conferences
04 août 2023 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update
10 mai 2023 16h05 HE
|
Rani Therapeutics, LLC
- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on...
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
22 mars 2023 16h05 HE
|
Rani Therapeutics, LLC
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - -...
ProLynx announces SBIR grant award to develop long-acting parathyroid hormone for hypo-parathyroidism
07 juil. 2020 09h00 HE
|
ProLynx LLC
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- Today ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH. The grant was conferred for the development of...